Aspirin May Significantly Lower the Risk of Pancreatic Cancer
The use of aspirin -- even low-dosage aspirin prescribed to guard against heart disease -- at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the annual meeting of the American Association for Cancer Research.
Dr. Xiang-Lin Tan, a research fellow at Mayo Clinic in Rochester, Minnesota, said the findings from this large collaborative study are preliminary and do not encourage widespread use of aspirin for this purpose.
“The results are not meant to suggest everyone should start taking aspirin once monthly to reduce their risk of pancreatic cancer,” said Tan. “Individuals should discuss use of aspirin with their physicians because the drug carries some side effects.”
Results showed that people who took aspirin at least one day during a month had a 26% decreased risk of pancreatic cancer compared to those who did not take aspirin regularly. The effect was also found for those who took low-dose aspirin for heart disease prevention at 35% lower risk, according to Tan.
The researchers did not see a benefit from non-aspirin NSAIDs or acetaminophen. “This provides additional evidence that aspirin may have chemoprevention activity against pancreatic cancer,” said Tan. He added that more data must be gathered before we can prove a real benefit.
Find with keyword(s): Enter a keyword or phrase to search CaregiversHome's archives for related news topics, the latest news stories, timely times, and reference articles.
Commercial use, redistribution or other forms of reuse of this information is strictly prohibited without the prior written permission of Pederson Publishing.